Janus Henderson Group PLC Has $29.07 Million Position in Tenax Therapeutics, Inc. $TENX

Janus Henderson Group PLC raised its stake in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) by 989.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,815,474 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,648,808 shares during the quarter. Janus Henderson Group PLC owned approximately 0.11% of Tenax Therapeutics worth $29,066,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in shares of Tenax Therapeutics in the 4th quarter worth about $5,353,000. Siren L.L.C. lifted its holdings in Tenax Therapeutics by 21.2% during the 4th quarter. Siren L.L.C. now owns 427,141 shares of the specialty pharmaceutical company’s stock valued at $5,207,000 after purchasing an additional 74,700 shares during the last quarter. Millennium Management LLC boosted its position in Tenax Therapeutics by 34.2% in the third quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock valued at $2,387,000 after buying an additional 79,998 shares in the last quarter. Marshall Wace LLP boosted its position in Tenax Therapeutics by 68.2% in the fourth quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company’s stock valued at $3,634,000 after buying an additional 120,944 shares in the last quarter. Finally, Diadema Partners LP bought a new stake in Tenax Therapeutics during the fourth quarter worth about $2,964,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Tenax Therapeutics Stock Performance

TENX opened at $13.70 on Monday. The stock has a market capitalization of $363.32 million, a PE ratio of -9.26 and a beta of 0.93. Tenax Therapeutics, Inc. has a 1-year low of $5.78 and a 1-year high of $19.40. The firm has a 50-day moving average price of $13.63 and a two-hundred day moving average price of $13.58.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. On average, research analysts predict that Tenax Therapeutics, Inc. will post -1.48 EPS for the current year.

Wall Street Analyst Weigh In

TENX has been the subject of several recent analyst reports. Piper Sandler raised their price objective on shares of Tenax Therapeutics from $20.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, June 12th. Cantor Fitzgerald restated an “overweight” rating and set a $35.00 price target on shares of Tenax Therapeutics in a research report on Wednesday, July 29th. Canaccord Genuity Group assumed coverage on Tenax Therapeutics in a report on Tuesday, July 28th. They set a “buy” rating and a $35.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday, June 30th. Finally, Evercore began coverage on Tenax Therapeutics in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $39.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $37.67.

Tenax Therapeutics Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.